Retour
53
36
11
4
20
Également cotée sous
CHGCY
OTC
Fourchette du Jour
51,94 €
64,01 €
Fourchette 52 Semaines
38,76 €
72,30 €
Volume
216
Moyenne 50J / 200J
58,19 €
/
51,05 €
Clôture Précédente
52,24 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 0,2 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 22,1 | 3,8 |
| Net Margin % | 34,5 | 3,9 |
| Rev Growth 5Y % | 5,9 | 10,0 |
| D/E | 0,0 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
531,16 €
488,31 € – 574,26 €
|
1900 B | 5 |
| FY2029 |
481,84 €
442,97 € – 520,94 €
|
1900 B | 2 |
| FY2028 |
392,11 €
360,48 € – 423,93 €
|
1600 B | 5 |
Points Clés
Revenue grew 5,93% annually over 5 years — modest growth
ROE of 22,11% indicates high profitability
Net margin of 34,50% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 313,45B in free cash flow
P/E of 0,20 — trading at a low valuation
Croissance
Revenue Growth (5Y)
5,93%
Revenue (1Y)7,55%
Earnings (1Y)12,15%
FCF Growth (3Y)-3,37%
Qualité
Return on Equity
22,11%
ROIC21,85%
Net Margin34,50%
Op. Margin46,92%
Sécurité
Debt / Equity
0,00
Current Ratio4,23
Interest Coverage575,24
Valorisation
P/E Ratio
0,20
P/B Ratio0,04
EV/EBITDA-0,58
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,55% | Revenue Growth (3Y) | 6,44% |
| Earnings Growth (1Y) | 12,15% | Earnings Growth (3Y) | 15,53% |
| Revenue Growth (5Y) | 5,93% | Earnings Growth (5Y) | 9,42% |
| Profitability | |||
| Revenue (TTM) | 1,26T | Net Income (TTM) | 434,39B |
| ROE | 22,11% | ROA | 17,58% |
| Gross Margin | 71,09% | Operating Margin | 46,92% |
| Net Margin | 34,50% | Free Cash Flow (TTM) | 313,45B |
| ROIC | 21,85% | FCF Growth (3Y) | -3,37% |
| Safety | |||
| Debt / Equity | 0,00 | Current Ratio | 4,23 |
| Interest Coverage | 575,24 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 0,20 | P/B Ratio | 0,04 |
| P/S Ratio | 0,07 | PEG Ratio | 2,68 |
| EV/EBITDA | -0,58 | Dividend Yield | 0,02% |
| Market Cap | 85,48B | Enterprise Value | -341,50B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,26T | 1,17T | 1,11T | 1,26T | 999,76B |
| Net Income | 434,39B | 387,32B | 325,47B | 374,43B | 303,00B |
| EPS (Diluted) | 263,95 | 235,36 | 197,80 | 227,57 | 184,17 |
| Gross Profit | 895,03B | 831,20B | 698,06B | 783,70B | 661,61B |
| Operating Income | 590,71B | 542,00B | 439,17B | 533,31B | 421,90B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,47T | 2,21T | 1,93T | 1,87T | 1,54T |
| Total Liabilities | 443,25B | 306,87B | 306,97B | 445,37B | 350,68B |
| Shareholders' Equity | 2,03T | 1,90T | 1,63T | 1,42T | 1,19T |
| Total Debt | 0,0 | 10,90B | 13,46B | 14,11B | 16,04B |
| Cash & Equivalents | 426,97B | 540,20B | 458,67B | 222,17B | 267,75B |
| Current Assets | 1,74T | 1,61T | 1,37T | 1,34T | 1,06T |
| Current Liabilities | 411,44B | 290,36B | 288,22B | 423,73B | 327,42B |
Scores de Stratégies
This stock passed the criteria for 5 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Capital Light Compounder
#47 of 213
#511 of 820
#527 of 658
#637 of 708
#183 of 195
Activité Récente
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Capital Light Compounder
Mar 24, 2026
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Entré
Value Investing (Warren Buffett)
Mar 24, 2026